You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in Estonia

Mar 2012

Price: US$2,400

About this Report

EXECUTIVE SUMMARY

Economy shows strong signs of recovery and sales increase

Consumer health demonstrated positive figures in 2011 after two years of decline. According to the Bank of Estonia, the local economy recovered rapidly and mainly due to increasing export demand. Still, with the external environment weakening, economy in Estonia is expected to record positive growth in 2012. Furthermore, consumers’ purchasing power started to grow in the third quarter of 2011 as their confidence in the economy was significantly higher and they started shopping more freely compared to previous years. A strong indicator is also the fact that value sales growth was driven by volume sales growth rather than increased prices. An ageing population is a supportive factor for OTC medicine sales.

Health organisations try to raise consumer awareness

Generic and economy medicines remain unpopular with consumers and health organisations attempted to change the situation with campaigns to increase consumer awareness about medicines’ active ingredients and prices. In 2010, The Health Insurance Fund launched the campaign “The difference is in the price of the medicine,” which is aimed to increase consumer awareness about the recipes that are based on active ingredients of medicines. The Fund tries to direct consumers to ask for medicine that has the same active ingredients but different prices, so they can make an informed decision. According to the Health Insurance Fund, the campaign has gathered positive feedback, which increases the popularity of economy brands. The Health Insurance Fund also continued with the social campaign in 2011.

International players strengthen their positions

Strong international companies increased their shares as they have more opportunities to invest in marketing. Local producers are mainly small companies, which lack resources and they cannot use expensive advertising on marketing their products, which gives strong advantage to international players. International companies also offer very good quality and efficient products and product quality became the most important characteristic in OTC medicines in 2011, which makes the situation even more complicated for domestic companies. Domestic producers try to emphasise their products’ domestic origins and they also try to use more natural ingredients as consumers usually expect this from local products.

Chemists/pharmacies hold the leading position

Chemists/pharmacies remained the leading distribution channel in 2011, because State Agency of Medicines regulations allow the sale of OTC medicines only through this channel. However, intense public debate over allowing OTC medicines sales in other channels continued. Medicine producers tried to convince officials to allow OTC medicines for sale in other retailing channels such as supermarkets and hypermarkets. Medicine producers highlighting aspects such as cigarettes being harmful to one’s health are available in most of the channels but smoking cessation medicines are available only from chemists/pharmacies. Most of the major retail companies have already approved their readiness for selling OTC medicines. In addition, the national postal service provider Eesti Post has claimed that its post offices are completely ready to take OTC medicines for sale. Officials have stated the contradictory positions on this topic.

Value sales expected to record steady growth over forecast period

Despite the rapid growth and positive events in the Estonian economy in 2011, growth is expected to slow down at the beginning of the forecast period. Still, value sales are expected to record positive growth which will see some improvements at the end of the forecast period. Figures remain rather modest, because consumer health is a stable, but continually growing environment in Estonia. A common view amongst companies surveyed is that medicine consumption will record steady growth because the Estonian population is ageing and older people consume more medicines than younger ones. Moreover, the development of medicines and new remedies is expected to support retail volume and value sales over the forecast period.


Samples (FAQs about samples):

doc_pdf.png Sample Consumer Health Market Research Report

doc_excel_table.png Sample Consumer Health Data

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in Estonia with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in Estonia, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in Estonia for free:

The Consumer Health in Estonia market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in Estonia?
  • What are the major brands in Estonia?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Table of Contents

Table of Contents

Consumer Health in Estonia - Industry Overview

EXECUTIVE SUMMARY

Economy shows strong signs of recovery and sales increase

Health organisations try to raise consumer awareness

International players strengthen their positions

Chemists/pharmacies hold the leading position

Value sales expected to record steady growth over forecast period

KEY TRENDS AND DEVELOPMENTS

Economic conditions help drive consumer health sales

Allowing OTC medicines for sale in other retailing channels

Estonian population is ageing

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2006-2011
  • Table 2 Life Expectancy at Birth 2006-2011

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2006-2011
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2006-2011
  • Table 5 Consumer Health Company Shares 2007-2011
  • Table 6 Consumer Health Brand Shares 2008-2011
  • Table 7 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
  • Table 8 Sales of Consumer Health by Category and Distribution Format: % Analysis 2010
  • Table 9 Forecast Sales of Consumer Health by Category: Value 2011-2016
  • Table 10 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016

APPENDIX

OTC registration and classification

Vitamins and dietary supplements registration and classification

Self-medication/self-care and preventative medicine

Switches

  • Summary 1 OTC Healthcare Switches 2009-2011

SOURCES

  • Summary 2 Research Sources

Consumer Health in Estonia - Company Profiles

Magnum Medical AS in Consumer Health (Estonia)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

Massuno OÜ in Consumer Health (Estonia)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 7 Massuno OÜ: Competitive Position 2011

Tallinna Farmaatsiatehase AS in Consumer Health (Estonia)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 10 Tallinna Farmaatsiatehase AS: Competitive Position 2011

Walmark spol sro in Consumer Health (Estonia)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 13 Walmark spol sro: Competitive Position 2011

Adult Mouth Care in Estonia - Category Analysis

HEADLINES

TRENDS

  • Adult mouth care increased by 4% in current value terms in 2011 as sales reached EUR0.17 million. Adult mouth care experienced significant decline during the crisis years as consumers attempted to reduce their costs on non-essential products. Together with a rise in consumer purchasing power, demand for adult mouth care increased as well. The economic situation allows consumers to pay more attention to oral hygiene and purchase more adult mouth care products.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline Plc led adult mouth care by holding value share of 19% with its products Corsodyl and Parodontax. The most popular brand in 2011 was Santoin by Walmark sro with 17% value share. These products are quite widely advertised compared to other products in this category and this is the main reason behind its strong performance.

PROSPECTS

  • Adult mouth care is expected to witness a constant value CAGR of 3% over the forecast period, reaching EUR0.20 million in 2016, which is also the pre-crisis level when the consumption was highest in Estonia. Adult mouth care is considered as immature and further growth is expected after exceeding pre-crisis growth rates in 2016. Furthermore, adult mouth care products are likely to gain significantly if the government withdraws restrictions over selling points of OTC medicines and they would become available in supermarkets and hypermarkets as well.

CATEGORY DATA

  • Table 11 Sales of Adult Mouth Care: Value 2006-2011
  • Table 12 Sales of Adult Mouth Care: % Value Growth 2006-2011
  • Table 13 Adult Mouth Care Company Shares 2007-2011
  • Table 14 Adult Mouth Care Brand Shares 2008-2011
  • Table 15 Forecast Sales of Adult Mouth Care: Value 2011-2016
  • Table 16 Forecast Sales of Adult Mouth Care: % Value Growth 2011-2016

Analgesics in Estonia - Category Analysis

HEADLINES

TRENDS

  • Analgesics displayed 3% current value growth as sales reached EUR8 million in 2011. Analgesics remains relatively popular in Estonia because it has acquired a miracle drug status in Estonia and many people believe that analgesics can help to relieve many symptoms and illnesses. Consumers also prefer analgesics to many other OTC medicines due to affordability. Estonians tend to use stronger OTC analgesics because the difference in prices is not so significant and it is more affordable to purchase stronger analgesics. Leading products are those with a 400mg concentration. Popularity of analgesics can also be seen in sales growth.

SWITCHES

COMPETITIVE LANDSCAPE

  • Category leader Nycomed SEFA AS managed to increase its share by one percentage point to hold 23% value share of total analgesics in 2011 in Estonia. Nycomed held a strong position in systemic analgesics with 32% value share and managed to increase its share in topical analgesics/anaesthetic to 6% in 2011 from 4% in 2010. The second biggest share holder was Berlin-Chemie AG with 13% share in 2011. GlaxoSmithKline Plc followed with 11% market share. These multinational companies heavily advertise their products via various media channels such as television, radio, printed media and the internet. Advertisement and quality of products led Estonian consumers to empathise with and trust multinational producers of consumer health products.

PROSPECTS

  • Analgesics is expected to reach EUR8.8 million in 2016 as its growth is predicted to display a 2% constant value CAGR over the forecast period. The Estonian economy is expected to meet strong recovery over the forecast period as consumers are expected to purchase and consume OTC analgesics more freely. Sales of analgesics are expected to exceed the pre-crisis level during the forecast period. At the end of 2011, there were active discussions in Estonia about OTC medicines becoming available through retailing channels such as supermarkets, hypermarkets and even through post offices. According to the Ministry of Social Affairs, OTC medicines becoming available in most of the retailing channels needs to be analysed very carefully and this will take time. If that decision comes in effect, analgesics would benefit from that.

CATEGORY DATA

  • Table 17 Sales of Analgesics by Category: Value 2006-2011
  • Table 18 Sales of Analgesics by Category: % Value Growth 2006-2011
  • Table 19 Analgesics Company Shares 2007-2011
  • Table 20 Analgesics Brand Shares 2008-2011
  • Table 21 Forecast Sales of Analgesics by Category: Value 2011-2016
  • Table 22 Forecast Sales of Analgesics by Category: % Value Growth 2011-2016

Calming and Sleeping in Estonia - Category Analysis

HEADLINES

TRENDS

  • Calming and sleeping products witnessed current value growth of 4% in 2011, with sales reaching EUR0.34 million. Consumers stopped trading down and began to value more quality than low prices. This was due to growing purchasing power and improving economic situation. Many consumers choose to repeat purchase OTC calming and sleeping products instead of visiting doctor because this helps to save time and is much more convenient.

SWITCHES

COMPETITIVE LANDSCAPE

  • Walmark spol sro maintained its leading position with a value share of 28% in 2011 as the company’s product Benosen N20 is well-known and valued by Estonian consumers, as well as being the best-selling calming and sleeping product in 2011. Other popular products were Palderjaniekstrakti Dražee by local company Dom Pharma OÜ which accounted for 14% value share and Massuno Unemati by Massuno OÜ with 13% value share.

PROSPECTS

  • Calming and sleeping is expected to display a 2% constant value CAGR over the forecast period, as sales reach EUR0.38 million in 2016. Further improvements in the economy and rising income are expected to increase calming and sleeping’s value sales.

CATEGORY DATA

  • Table 23 Sales of Calming and Sleeping: Value 2006-2011
  • Table 24 Sales of Calming and Sleeping: % Value Growth 2006-2011
  • Table 25 Calming and Sleeping Company Shares 2007-2011
  • Table 26 Calming and Sleeping Brand Shares 2008-2011
  • Table 27 Forecast Sales of Calming and Sleeping: Value 2011-2016
  • Table 28 Forecast Sales of Calming and Sleeping: % Value Growth 2011-2016

Cough, Cold and Allergy (Hay Fever) Remedies in Estonia - Category Analysis

HEADLINES

TRENDS

  • Cough, cold and allergy (hay fever) remedies recorded a strong performance as current value sales increased by 6% to reach EUR9.5 million in 2011. The winter at the beginning of 2011 was very snowy and cold, which led to an increase in demand for cough, cold and allergy (hay fever) remedies.

SWITCHES

COMPETITIVE LANDSCAPE

  • McNeil Products Ltd held the leading position with 21% value share in 2011. The company’s most popular product is Sudafed, which holds 10% value share of total sales in cough, cold and allergy (hay fever) remedies in 2011. GlaxoSmithKline retained the second leading position, with 15% value share due to the strength of its popular Coldrex brand, which is available in different flavours. Coldrex held 8% value share in 2011. Sudafed and Coldrex enjoyed best shelf positioning and were extensively advertised on television, printed media and online channels. In addition, these brands are well-known amongst consumers and many people regard those products as reliable OTC medicines.

PROSPECTS

  • Cough, cold and allergy (hay fever) remedies is predicted to reach EUR10.7 million in 2016 after recording a constant value CAGR of 3% over the forecast period. Cough, cold and allergy (hay fever) remedies sales are strongly seasonal but as consumers’ purchasing power increases, they are expected to purchase these products more freely and trade up to premium products, which is the main reason for growth.

CATEGORY DATA

  • Table 29 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 30 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 31 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares 2007-2011
  • Table 32 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares 2008-2011
  • Table 33 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2011-2016
  • Table 34 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2011-2016

Digestive Remedies in Estonia - Category Analysis

HEADLINES

TRENDS

  • Digestive remedies value sales increased by 4% to reach EUR3.5 million in 2011. Overall economic improvements allowed consumers to marginally trade up in digestive remedies and most of the segments posted a strong performance. Furthermore, for the first time after the crisis, consumers considered a product’s quality as a more important factor than price and this supported digestive remedies’ sales.

SWITCHES

COMPETITIVE LANDSCAPE

  • Berlin-Chemie AG remained the leader with 16% market share in value terms in 2011. Berlin-Chemie AG is marketing its popular brand Espumisan and Mezym Forte. Espumisan is well-known and trusted brand in Estonia due to its efficiency and company’s great efforts on marketing. Another biggest market share owners were Krewel Meuselbach GmbH and Solvay Pharmaceuticals Oy with 9% and 8% respectively.

PROSPECTS

  • Digestive remedies is predicted to reach EUR3.8 million in 2016 with a constant value CAGR of 1% over the forecast period. Digestive remedies recorded -0.5% constant value sales growth in 2011 and review period CAGR of -2%. Growth over the forecast period is expected to be higher in constant terms. Digestive remedies is set to record strongest growth rates during the first three years in the forecast period and growth rates are expected to tail off towards the end of the forecast period.

CATEGORY DATA

  • Table 35 Sales of Digestive Remedies by Category: Value 2006-2011
  • Table 36 Sales of Digestive Remedies by Category: % Value Growth 2006-2011
  • Table 37 Digestive Remedies Company Shares 2007-2011
  • Table 38 Digestive Remedies Brand Shares 2008-2011
  • Table 39 Forecast Sales of Digestive Remedies by Category: Value 2011-2016
  • Table 40 Forecast Sales of Digestive Remedies by Category: % Value Growth 2011-2016

Ear Care in Estonia - Category Analysis

HEADLINES

TRENDS

  • Ear care recorded 6% current value growth in 2011 with sales remaining at EUR0.03 million. Ear care is a very small category and 6% gain in value sales is rather marginal. The growth was influenced by consumers’ rising purchasing power and previously postponed purchases during the economic crisis. Still, ear care products are often neglected and consumers do not assess the risks involved with using cotton wool buds very seriously.

SWITCHES

COMPETITIVE LANDSCAPE

  • Naveh Pharma Ltd maintained its leading position with 61% value share in 2011. Sigmapharm GmbH retained its second position with value share of 38%. Both companies offer valued products which are well-known by consumers due to a narrow selection on offer.

PROSPECTS

  • Ear care is expected to display a constant value CAGR of 1% over the forecast period as sales stagnate. This low but positive growth is expected over the forecast period because the Estonian population is ageing and older tend people to purchase more health care products in general. In addition, consumers’ increased purchasing power will support ear care sales as consumers do not have to limit their expenditure.

CATEGORY DATA

  • Table 41 Sales of Ear Care: Value 2006-2011
  • Table 42 Sales of Ear Care: % Value Growth 2006-2011
  • Table 43 Ear Care Company Shares 2007-2011
  • Table 44 Ear Care Brand Shares 2008-2011
  • Table 45 Forecast Sales of Ear Care: Value 2011-2016
  • Table 46 Forecast Sales of Ear Care: % Value Growth 2011-2016

Emergency Contraception in Estonia - Category Analysis

HEADLINES

TRENDS

  • Emergency contraception current value sales increased by 5% with value sales reaching EUR0.5 million in 2011. Emergency contraception posted a very strong performance after the economic crisis ended and consumer purchasing power rose for the first time after eleven consecutive quarters of decline: some women consider these products to be essential. Escapelle 1.5mg and Postinor-2 were the only two products available in 2011.

COMPETITIVE LANDSCAPE

  • Richter Gedeon remains the only supplier of emergency contraception products in Estonia. The company markets two well-known products Postinor-2 and Escapelle 1.5mg. Postinor-2 contains two tablets and Escapelle 1.5mg contains one tablet. Escapelle 1.5mg is considered as a more convenient product, and is therefore more popular in Estonia. In 2011, Escapelle 1.5mg accounted for 62% value share and Postinor-2 for 38% value share.

PROSPECTS

  • Emergency contraception is predicted to reach EUR0.51 million in 2016 as sales will stagnate over the forecast period. Emergency contraception sales are expected to stagnate because it is not expected to meet significant volume sales demand and the economic situation does not influence sales significantly. In addition, new innovative contraceptives are being launched and the demand for emergency contraception is not likely to increase.

CATEGORY DATA

  • Table 47 Sales of Emergency Contraception: Value 2006-2011
  • Table 48 Sales of Emergency Contraception: % Value Growth 2006-2011
  • Table 49 Emergency Contraception Company Shares 2007-2011
  • Table 50 Emergency Contraception Brand Shares 2008-2011
  • Table 51 Forecast Sales of Emergency Contraception: Value 2011-2016
  • Table 52 Forecast Sales of Emergency Contraception: % Value Growth 2011-2016

Eye Care in Estonia - Category Analysis

HEADLINES

TRENDS

  • Eye care grew by 5% in current value terms to record sales of EUR0.7 million in 2011 in Estonia. Instead of saving money and reducing expenditure, consumers started to pay more attention to their health, which in turn increased the purchase of eye care products. Another supportive factor was that real wages started to grow in the third quarter of 2011 after the decrease lasting for eleven consecutive quarters.

SWITCHES

COMPETITIVE LANDSCAPE

  • Nycomed SEFA AS was the undisputed leader of eye care in 2011 with 70% value share, leaving all the competitors far behind. Nycomed’s most popular product is Sulfametizol and this is considered as a very efficient remedy. Pfizer Inc ranked second with a retail value share of 9% and Alcon-Couvreur SA NV was ranked third with value share of 8% in 2011.

PROSPECTS

  • Eye care is expected to see a constant value CAGR of 1% over the forecast period as sales reach EUR0.8 million by 2016. Eye care is a fairly mature category in Estonia but growth is still predicted as the population is ageing and increasingly more people are expected to work with computers, which is tiring for eyes and increases the demand for eye care supplements.

CATEGORY DATA

  • Table 53 Sales of Eye Care by Category: Value 2006-2011
  • Table 54 Sales of Eye Care by Category: % Value Growth 2006-2011
  • Table 55 Standard Eye Care by Format: % Value Breakdown 2007-2011
  • Table 56 Standard Eye Care by Positioning 2007-2011
  • Table 57 Eye Care Company Shares 2007-2011
  • Table 58 Eye Care Brand Shares 2008-2011
  • Table 59 Forecast Sales of Eye Care by Category: Value 2011-2016
  • Table 60 Forecast Sales of Eye Care by Category: % Value Growth 2011-2016

Herbal/Traditional Products in Estonia - Category Analysis

HEADLINES

TRENDS

  • Herbal/traditional products value sales rose by 4% as EUR3.4 million sales were recorded in 2011 in Estonia. The economic situation improved rapidly during 2011 and it also led to an increase in salaries. Consumers started opting for healthier products and this increased herbal/traditional products’ sales.

COMPETITIVE LANDSCAPE

  • International player Dansk Droge A/S retained its leading position with 7% value share in herbal/traditional products. It sells its Gerimax brand in Estonia which is very well-known and valued by Estonians. Gerimax tinctures are often purchased as a present to older people. The leader was followed by Pharma Nord ApS and Richard Bittner GmbH with value sales shares of 6% and 5% respectively.

PROSPECTS

  • Herbal/traditional products is predicted to grow by a 1% constant value CAGR as sales will increase to EUR3.5 million in 2016. Positive growth is predicted as the economy is expected to improve over the early part of the forecast period and consumer’s awareness about health trends and herbal/traditional products is increasing. Future trends will include ongoing health trends which will lead consumers to demand healthier products and this is expected to increase herbal/traditional products sales.

CATEGORY DATA

  • Table 61 Sales of Herbal/Traditional Products: Value 2006-2011
  • Table 62 Sales of Herbal/Traditional Products: % Value Growth 2006-2011
  • Table 63 Herbal/Traditional Products Company Shares 2007-2011
  • Table 64 Herbal/Traditional Products Brand Shares 2008-2011
  • Table 65 Forecast Sales of Herbal/Traditional Products: Value 2011-2016
  • Table 66 Forecast Sales of Herbal/Traditional Products: % Value Growth 2011-2016

Medicated Skin Care in Estonia - Category Analysis

HEADLINES

TRENDS

  • Medicated skin care witnessed current value growth of 5% to reach EUR1.6 million in 2011 due to increased consumption. Consumers purchased medicated skin care products more freely in 2011 because of increased economic confidence increased as the average nominal wage rose. In addition, the news flow in media channels became more positive as many local companies posted very strong results compared to previous years and unemployment decreased as well. Due to many positive factors, consumers’ attention was not as focused on savings and they therefore started to make purchases which they previously postponed.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline Plc maintained its leadership to account for 36% value share in 2011. GlaxoSmithKline sells its remedies Nix and Zovirax in Estonia and these products are very valued by consumers. Both remedies accounted for 11% value share each in 2011. GlaxoSmithKline invests a great deal in advertising and its products occupy the best shelf positions in pharmacies. Beiersdorf AG and Novartis AG accounted for value sales share of 13% and 7% respectively. Beiersdorf’s most popular product is Eucerin and Novartis AG is well-known because of its brands Fenivir and Lamisil.

PROSPECTS

  • Medicated skin care is expected to reach constant value sales of EUR1.7 million in 2016 to exceed pre-crisis levels. This performance will be due to volume sales growth as consumers will increase their consumption. Herbal/traditional medicated skin care products is also predicted to show the strong performance over the forecast period with a 3% constant value CAGR, mainly driven by health trends that rapidly gather popularity among consumers.

CATEGORY DATA

  • Table 67 Sales of Medicated Skin Care by Category: Value 2006-2011
  • Table 68 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
  • Table 69 Medicated Skin Care Company Shares by Value 2007-2011
  • Table 70 Medicated Skin Care Brand Shares 2008-2011
  • Table 71 Hair Loss Treatments Brand Shares 2008-2011
  • Table 72 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
  • Table 73 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016

NRT Smoking Cessation Aids in Estonia - Category Analysis

HEADLINES

TRENDS

  • NRT smoking cessation aids reached EUR0.38 million in 2011 as current value sales grew by 7%. Cigarettes prices are constantly increasing for consumers and many smokers search for opportunities to make quitting easier. According to Statistics Estonia, cigarette prices increased by 6% in 2011 and [Q: this gave an important drive for consumers to make the decision to quit smoking. Moreover, the healthy lifestyle trend continued to gain momentum and tolerance against smokers continued to fall in Estonia. Also smoking prevalence is in decline and male smoking population % rate declined to below 42%. Female smoking prevalence is also in constant decline and 17% of adult female population were smokers in Estonia in 2011.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline Plc led the category with a value share of 55% in 2011. The company was successful due to excessive advertising campaigns and good positioning of products in chemists/pharmacies. GlaxoSmithKline sells its well-known brand Niquitin which has a very good reputation in Estonia. Also the selection of products is rather modest in NRT smoking cessation aids in Estonia and available products show a strong performance.

PROSPECTS

  • NRT smoking cessation aids is set to display a constant value CAGR of 6% to reach EUR0.50 million in 2016. The economic crisis restored the habit of saving and quitting smoking is considered as a way to save money. In addition, the increasing trend of a healthy lifestyle and increasing prices of cigarettes led consumers to seek help from medical NRT smoking cessation aids, which in turn will increase sales for this category over the forecast period.

CATEGORY INDICATORS

  • Table 74 Number of Smokers by Gender 2006-2011

CATEGORY DATA

  • Table 75 Sales of NRT Smoking Cessation Aids by Category: Value 2006-2011
  • Table 76 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2006-2011
  • Table 77 NRT Gum Flavours: % Value Breakdown 2006-2011
  • Table 78 NRT Smoking Cessation Aids Company Shares 2007-2011
  • Table 79 NRT Smoking Cessation Aids Brand Shares 2008-2011
  • Table 80 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2011-2016
  • Table 81 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2011-2016

OTC Triptans in Estonia - Category Analysis

TRENDS

  • Triptans are only available as Rx medicine in Estonia. Triptans which are prescribed include Zolmitriptan Actavis 5mg (produced by Actavis Ltd), Imigran (produced by GlaxoSmithKline), Sumatriptan Sandoz (produced by Sandoz) and Cinie (produced by Zentiva).

Sports Nutrition in Estonia - Category Analysis

HEADLINES

TRENDS

  • Sports nutrition current value sales witnessed a 1% decline in 2011 as sales reached EUR4.95 million in 2011. Although consumers’ purchasing power started to grow in the third quarter of 2011, consumers were unwilling to increase their expenditure on sports nutrition. They continued to find these products non-essential and saw other products as more needed. However, the decline slowed down and sports nutrition is set to start growing in the coming years. Sports nutrition distribution in expanding into mass channels like supermarkets/hypermarkets, but also into online channel.

COMPETITIVE LANDSCAPE

  • Fast Sports Nutrition maintained its leading position in sports nutrition with 23% value sales share in 2011. Fast Sports Nutrition markets a wide range of sports nutrition in Estonia including leading brand Hera80 and its products were one of the first to become available in supermarkets and hypermarkets. Therefore, Fast Sports Nutrition is considered to offer high quality products and many consumers value them.

PROSPECTS

  • Sports nutrition is expected to record a 2% constant value CAGR over the forecast period as sales reach EUR5.5 million in 2016 in Estonia. The growth is expected because consumers are likely to increase their expenditure on sports nutrition if they experience further income recovery. Moreover, with the ever growing popularity of the health and wellness trend, many people will choose to use sports nutrition whilst training to increase efficiency.

CATEGORY DATA

  • Table 82 Sales of Sports Nutrition: Value 2006-2011
  • Table 83 Sales of Sports Nutrition: % Value Growth 2006-2011
  • Table 84 Sports Nutrition Company Shares 2007-2011
  • Table 85 Sports Nutrition Brand Shares 2008-2011
  • Table 86 Forecast Sales of Sports Nutrition: Value 2011-2016
  • Table 87 Forecast Sales of Sports Nutrition: % Value Growth 2011-2016

Vitamins and Dietary Supplements in Estonia - Category Analysis

HEADLINES

TRENDS

  • Vitamins and dietary supplements reached value sales of EUR10 million in 2011, increasing by 5%. Increasing consumer purchasing power supports vitamins and dietary supplements sales in Estonia. There is a wide selection of vitamins and dietary supplements available in Estonia and consumers can choose between different price ranges.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Walmark spol sro became the overall leader in 2011 with its 9% value share due to a wide range of valued and well-known products. The second biggest share holder was Nycomed SEFA which held marginally less share than the leader. Both companies are trying to position their products in order to increase their value sales shares and invested a great deal into advertising.

PROSPECTS

  • Vitamins and dietary supplements is expected to reach EUR11 million in 2016, recording a constant value CAGR of 1% over the forecast period. Modest growth is expected over the forecast period as the economic improvements and rising prices are expected to support value sales as consumers find they can afford to trade up to premium products.

CATEGORY DATA

  • Summary 14 Dietary Supplements: Brand Ranking by Positioning 2011
  • Table 88 Sales of Vitamins and Dietary Supplements by Category: Value 2006-2011
  • Table 89 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2006-2011
  • Table 90 Dietary Supplements by Positioning 2007-2011
  • Table 91 Vitamins and Dietary Supplements Company Shares 2007-2011
  • Table 92 Vitamins and Dietary Supplements Brand Shares 2008-2011
  • Table 93 Vitamins Brand Shares 2008-2011
  • Table 94 Dietary Supplements Brand Shares 2008-2011
  • Table 95 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2011-2016
  • Table 96 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2011-2016

Weight Management in Estonia - Category Analysis

HEADLINES

TRENDS

  • Weight management increased by 2% in current value terms to reach EUR0.5 million in 2011. Growth was due to economic influences as consumer purchasing power and economic confidence rose. According to Statistics Estonia, real wages which shows the purchasing power of wages and salaries, increased by 1.2% in the third quarter of 2011.

COMPETITIVE LANDSCAPE

  • Glaxo Group Ltd continued to lead weight management value sales by holding a 58% share in 2011. The company markets its well-known product Alli in Estonia which has gathered a great deal of negative feedback from consumers due to negative side effects like vomiting, but still remained fairly popular. Alli is still receiving intensive advertising despite the feedback. Laboratoires Pierre Fabre SA and Erba Vita followed the leader with value sales shares of 8%.

PROSPECTS

  • Weight management is expected to grow by a constant value CAGR of 1% over the forecast period. Further improvements in the Estonian economy and consumers’ income are expected to increase weight management sales because consumers tend to use more weight management products to balance their dieting beside active lifestyles. Another reason is a lack of time, why consumers cannot go to regular training sessions and have to use substitute products. However, the growth is expected to be slower compared to review period, as the category will be about finalizing its consumers base.

CATEGORY DATA

  • Table 97 Sales of Weight Management by Category: Value 2006-2011
  • Table 98 Sales of Weight Management by Category: % Value Growth 2006-2011
  • Table 99 Weight Management Company Shares 2007-2011
  • Table 100 Weight Management Brand Shares 2008-2011
  • Table 101 Forecast Sales of Weight Management by Category: Value 2011-2016
  • Table 102 Forecast Sales of Weight Management by Category: % Value Growth 2011-2016

Wound Care in Estonia - Category Analysis

HEADLINES

TRENDS

  • Current retail value sales of wound care increased by 6%, reaching EUR0.73 million in 2011. Many consumers begin to restock their wound care products following increased purchasing power.

COMPETITIVE LANDSCAPE

  • Competition remained intense within wound care as Beiersdorf AG managed to retain its lead with 49% value share in 2011. Beiersdorf’s most popular brand is Hansaplast, which offers very wide variety of wound care products in Estonia. Hansaplast has special products targeted to adults and children. Beiersdorf also invests heavily in advertising and its Hansaplast products are well-known and valued in Estonia.

PROSPECTS

  • Wound care is expected to grow by a 1% constant value CAGR over the forecast period to reach EUR0.77 million in 2016. Wound care is a mature category and after 2011’s good results, it is expected to record steady annual value sales growth. Value sales are expected to increase due to increase in unit prices and due to trading up to more quality products.

CATEGORY DATA

  • Table 103 Sales of Wound Care by Category: Value 2006-2011
  • Table 104 Sales of Wound Care by Category: % Value Growth 2006-2011
  • Table 105 Wound Care Company Shares 2007-2011
  • Table 106 Wound Care Brand Shares 2008-2011
  • Table 107 Forecast Sales of Wound Care by Category: Value 2011-2016
  • Table 108 Forecast Sales of Wound Care by Category: % Value Growth 2011-2016

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Paediatric Analgesics
            • Paediatric Acetaminophen
            • Paediatric Aspirin
            • Paediatric Combination Products - Analgesics
            • Paediatric Diclofenac
            • Paediatric Dipyrone
            • Paediatric Ibuprofen
            • Paediatric Ketoprofen
            • Paediatric Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Paediatric Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
      • Protein Products
        • Bars
        • Powder
        • RTD
        • Other Protein
      • Non-Protein Products
    • Vitamins and Dietary Supplements
      • Paediatric Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
          • Non-Herbal Dietary Supplements
            • Calcium Supplements
            • Co-Enzyme Q10
            • Combination Non-Herbal Dietary Supplements
            • Eye Health Supplements
            • Fish Oils
              • Cod Liver Oil
              • Other Fish Oils
            • Glucosamine
            • Mineral Supplements
            • Omega-3-6-9 (Fish and Non-Fish)
            • Probiotic Supplements
            • Protein Powder
            • Royal Jelly
            • Sam-E
            • Other Non-Herbal Dietary Supplements
          • Tonics and Bottled Nutritive Drinks
          • Vitamins
            • Multivitamins
            • Single Vitamins
              • Vitamin A
              • Vitamin B
              • Vitamin C
              • Vitamin D
              • Vitamin E
              • Other Single Vitamins
        • Weight Management
          • Meal Replacement Slimming
          • OTC Obesity
          • Slimming Teas
          • Weight Loss Supplements
          • Other Slimming Products
        • Herbal/Traditional Products
          • Herbal/Traditional Analgesics
          • Herbal/Traditional Calming and Sleeping Products
          • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
          • Herbal/Traditional Digestive Remedies
          • Herbal/Traditional Medicated Skin Care
          • Herbal/Traditional Medicinal Teas
          • Herbal/Traditional Smoking Cessation Aids
          • Herbal/Traditional Paediatric Dietary Supplements
          • Herbal/Traditional Dietary Supplements
          • Herbal/Traditional Tonics and Bottled Nutritive Drinks
        • Allergy Care
          • Allergy Eye Care
          • Antihistamines/Allergy Remedies (Systemic)
          • Paediatric Allergy Remedies
          • Topical Allergy Remedies/Antihistamines
        • Paediatric Consumer Health
          • Paediatric Analgesics
            • Paediatric Acetaminophen
            • Paediatric Aspirin
            • Paediatric Combination Products - Analgesics
            • Paediatric Diclofenac
            • Paediatric Dipyrone
            • Paediatric Ibuprofen
            • Paediatric Ketoprofen
            • Paediatric Naproxen
          • Paediatric Cough, Cold and Allergy Remedies
            • Paediatric Allergy Remedies
            • Paediatric Cough/Cold Remedies
          • Paediatric Digestive Remedies
            • Paediatric Diarrhoeal Remedies
            • Paediatric Indigestion and Heartburn Remedies
            • Paediatric Laxatives
            • Paediatric Motion Sickness Remedies
          • Paediatric Medicated Skin Care
          • Nappy (Diaper) Rash Treatments
          • Paediatric Vitamins and Dietary Supplements

      Statistics Included

      Statistics Included

      For each category and subcategory you will receive the following data in Excel format:

      From Passport

      • Market sizes
      • Company shares
      • Brand shares
      • Distribution
      • Analysis by format
      • Analysis by positioning
      • Analysis by type
      • Herbal/traditional vs standard
      • Pricing
      • Smoking population - number of adult smokers
      • Smoking prevalence - % of adult population

      Market size details:

      • Retail volume
      • Retail volume % growth
      • Retail volume per capita
      • Retail value retail selling price % growth
      • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
      • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price % growth
      • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY

      Methodology

      Methodology

      Global insight and local knowledge

      With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

      This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

      Industry specialists

      Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

      Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

      The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

      Country and regional analysts

      Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

      In-country research network

      To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

      Research Methodology

      Our research methods

      Each Euromonitor International industry report is based on a core set of research techniques:

      Desk research

      With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

      • National statistics offices governmental and official sources
      • National and international trade press
      • National and international trade associations
      • Industry study groups and other semi-official sources
      • Company financials and annual reports
      • Broker reports
      • Online databases
      • The financial, business and mainstream press

      Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

      Store checks

      Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

      • Place: We track products in all relevant channels, selective and mass, store and non-store
      • Product: What are innovations in products, pack sizes and formats?
      • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
      • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

      Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

      Trade survey

      Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

      Trade surveys allow us to:

      • Fill gaps in available published data per company
      • Generate a consensus view of the size, structure and strategic direction of the category
      • Access year-in-progress data where published sources are out of date
      • Evaluate the experts’ views on current trends and market developments

      In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

      Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

      Company analysis

      At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

      At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

      Forecasts

      Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

      Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

      Data validation

      All data is subjected to an exhaustive review process, at country, regional and global levels.

      The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

      Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

      Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

      Market analysis

      Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

      Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

      my pages

      Want to find out more about this report?

      If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!